Vimarsana
Biggest News Aggregation in the World

Page 16 - Eachf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eachf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eachf Today - Breaking & Trending Today

EQS-News: FiCAS AG reaches two further milestones: CHF 10 Mio. AuM; YTD Performance over 100% - Vimarsana News

EQS-News: FiCAS AG reaches two further milestones: CHF 10 Mio. AuM; YTD Performance over 100%

EQS-News: FiCAS AG reaches two further milestones: CHF 10 Mio. AuM; YTD Performance over 100% vom 19.02.2021, 17:50 Uhr Bild: pixabay.com FiCAS AG reaches two further milestones: CHF 10 Mio. AuM; YTD Performance over 100% 19.02.2021 / 17:50 CHF 10 Mio. AuM; YTD Performance over 100% Today FiCAS AG has passed the cap of CHF 10 million AuM. The 15 FiCAS Active Crypto ETP (ISIN CH0548689600) records a performance in excess of 100% year-to-date. Zug, Switzerland - 19 February 2021 - FiCAS AG has reached over CHF 10 million of Asset under Management in its unique "15 FiCAS Active Crypto ETP", l...

First Drug Approved for Some HFpEF - Vimarsana News

First Drug Approved for Some HFpEF

email article Sacubitril/valsartan (Entresto) became the first drug to get a broad heart failure indication that reaches into the normal ejection fraction range for prevention of cardiovascular death and hospitalization, Novartis announced. FDA granted the drug an expanded indication "to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal." An advisory committee weighing approval in December voted unanimously in...

Clariant : delivers robust performance in 2020, successfully… - Vimarsana News

Clariant : delivers robust performance in 2020, successfully…

Sales from continuing operations decreased by 5 % in local currency to CHF 3.860 billion EBITDA margin preserved at 15.0 % in a challenging environment... | February 14, 2021

NOVARTIS AG : Goldman Sachs reiterates its Buy rating - Vimarsana News

NOVARTIS AG : Goldman Sachs reiterates its Buy rating

Analyst Keyur Parekh from Goldman Sachs research considers the stock attractive and recommends it with a Buy rating. The target price has been modified and is now set at CHF 106 compared to CHF 109. | February 6, 2021

CNN Anderson Cooper 360 October 10, 2019 00:27:00 - Vimarsana News

CNN Anderson Cooper 360 October 10, 2019 00:27:00

United states. >> they believed they would be protected. >> absolutely. >> -- and honored. >> yes. and we just threw them under the bus in 24 hours. it is appalling. and it's disgraceful. and then today when the turks quite predictably are bombing the jesus out of syria, and trump allegedly orders the u.s. military not to come to their defense, not to protect them. we've crossed a rubicon here of betrayal that i think is going to haunt us for decades to come. >> the end of when south vietnam finally fell there were a lot of people who helped the united states left behind who weren't evacuated....